These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27194435)

  • 1. Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia.
    Nightingale S; Geretti AM; Beloukas A; Fisher M; Winston A; Else L; Nelson M; Taylor S; Ustianowski A; Ainsworth J; Gilson R; Haddow L; Ong E; Watson V; Leen C; Minton J; Post F; Pirmohamed M; Solomon T; Khoo S
    J Neurovirol; 2016 Dec; 22(6):852-860. PubMed ID: 27194435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.
    Dravid AN; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Wadia RS
    Medicine (Baltimore); 2018 Feb; 97(8):e9969. PubMed ID: 29465595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults.
    Mukerji SS; Misra V; Lorenz D; Cervantes-Arslanian AM; Lyons J; Chalkias S; Wurcel A; Burke D; Venna N; Morgello S; Koralnik IJ; Gabuzda D
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):246-255. PubMed ID: 28328546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.
    Kravcik S; Gallicano K; Roth V; Cassol S; Hawley-Foss N; Badley A; Cameron DW
    J Acquir Immune Defic Syndr; 1999 Aug; 21(5):371-5. PubMed ID: 10458617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
    Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
    AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
    Anderson AM; Muñoz-Moreno JA; McClernon DR; Ellis RJ; Cookson D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Franklin DR; Heaton RK; Grant I; Letendre SL;
    J Infect Dis; 2017 Jan; 215(1):105-113. PubMed ID: 27789723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.
    Premeaux TA; D'Antoni ML; Abdel-Mohsen M; Pillai SK; Kallianpur KJ; Nakamoto BK; Agsalda-Garcia M; Shiramizu B; Shikuma CM; Gisslén M; Price RW; Valcour V; Ndhlovu LC
    J Neurovirol; 2019 Apr; 25(2):150-161. PubMed ID: 30478799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.
    Vardhanabhuti S; Taiwo B; Kuritzkes DR; Eron JJ; Bosch RJ
    Antivir Ther; 2015; 20(1):73-6. PubMed ID: 24699164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.
    Delaugerre C; Gallien S; Flandre P; Mathez D; Amarsy R; Ferret S; Timsit J; Molina JM; de Truchis P
    PLoS One; 2012; 7(5):e36673. PubMed ID: 22590588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF.
    Nightingale S; Michael BD; Fisher M; Winston A; Nelson M; Taylor S; Ustianowski A; Ainsworth J; Gilson R; Haddow L; Ong E; Leen C; Minton J; Post F; Beloukas A; Borrow R; Pirmohamed M; Geretti AM; Khoo S; Solomon T
    Cytokine; 2016 Jul; 83():139-146. PubMed ID: 27131579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.
    Mukerji SS; Misra V; Lorenz DR; Uno H; Morgello S; Franklin D; Ellis RJ; Letendre S; Gabuzda D
    Clin Infect Dis; 2018 Sep; 67(8):1182-1190. PubMed ID: 29617912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.
    Spudich SS; Nilsson AC; Lollo ND; Liegler TJ; Petropoulos CJ; Deeks SG; Paxinos EE; Price RW
    BMC Infect Dis; 2005 Nov; 5():98. PubMed ID: 16266436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape.
    de Almeida SM; Rotta I; de Pereira AP; Tang B; Umlauf A; Ribeiro CEL; Letendre S; Ellis RJ;
    J Neurovirol; 2020 Apr; 26(2):241-251. PubMed ID: 32002817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations.
    Palich R; Wirden M; Peytavin G; Lê MP; Seang S; Abdi B; Schneider L; Tubiana R; Valantin MA; Paccoud O; Soulié C; Calvez V; Katlama C; Marcelin AG
    J Antimicrob Chemother; 2020 Oct; 75(10):2981-2985. PubMed ID: 32642769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure.
    Maggiolo F; Callegaro A; Cologni G; Bernardini C; Velenti D; Gregis G; Quinzan G; Soavi L; Iannotti N; Malfatto E; Leone S
    J Acquir Immune Defic Syndr; 2012 Aug; 60(5):473-82. PubMed ID: 22481602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV.
    Trunfio M; Rugge W; Mighetto L; Vai D; Atzori C; Nigra M; Domini S; Borgogno E; Guastamacchia G; Bonora S; Di Perri G; Calcagno A
    AIDS; 2020 Nov; 34(13):1899-1906. PubMed ID: 32701580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
    Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
    J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing low-level HIV viraemia in antiretroviral therapy: a systematic review and meta-analysis.
    Zaçe D; Rindi LV; Compagno M; Colagrossi L; Santoro MM; Andreoni M; Perno CF; Sarmati L;
    Sex Transm Infect; 2024 Oct; 100(7):460-468. PubMed ID: 39288983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana.
    Kelentse N; Moyo S; Mogwele M; Lechiile K; Moraka NO; Maruapula D; Seatla KK; Esele L; Molebatsi K; Leeme TB; Lawrence DS; Musonda R; Kasvosve I; Harrison TS; Jarvis JN; Gaseitsiwe S
    Medicine (Baltimore); 2020 Oct; 99(41):e22606. PubMed ID: 33031315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.